King George's Medical University, Chowk, Lucknow U.P. INDIA
  • About Us
  • Contact Us

Close
  • Home
  • Campus
    • History
    • Alumni
    • Campus
      • About The Campus
      • Campus Map
      • Campus Glimpses
      • MCI PG regulations 2000
    • Facilities
      • Hostels
      • Gender Harassment Complaint Cell
      • Guest House
    • Scientific Convention Centre
    • Important Contact Numbers
  • Administration
    • KGMU Act
    • Statute 2011
    • EC Regulations 2018
    • UGC Regulations 2018
    • Statement
    • Chancellor
    • Vice Chancellor
    • Executive Council Minutes
    • Academic Council
    • Officers
    • In-charge of Sections
    • Finance
    • University Court
    • Registered Graduates
      • Applicaiton Form
    • Government Order (GO)
  • Faculty
    • Faculty of Medical Sciences
    • Faculty of Dental Sciences
      • Education Overview
      • Message From The Dean
      • Department
      • Course/ Admission
      • Anti-Ragging Information
      • Picture Gallery
      • Dental Graduates: Journey Ahead
    • Institute of Paramedical Sciences
    • Institute of Nursing
    • Faculty Members
    • Departments
    • Affiliated Colleges
  • Education
    • Library
      • About Library
      • Advisory Committee
      • Team of Central Library
      • Library Rules
      • Library Services
      • Library Hours
      • Library Resources
      • Audio-Visual Material
      • OPAC
      • Print Journals 2018-19
      • List of Book
      • Usefull Links
      • Glimpses
      • Ask a Libraian !
      • Library Events Happening
    • Research
      • Research
      • Research Activities
      • Ongoing Research Projects
        • Extramural Faculty
      • Consent Form & Check List
      • DHR MRU
      • ATLS (Advance Trauma Life Support)
      • ATCN (Advance Trauma Care for Nurses)
      • Biosafety Committee
    • UG Teaching Schedule
    • Student Zone
      • Student Associations
      • SR/JRs Emails List
      • Events
      • Hostel
      • Mentor List of MBBS & BDS 2016
    • Picture Gallery
    • Enrollment Data
      • Enrollment Data 2008-2013
      • Enrollment Data 2014-2015
      • Enrollment Data 2015-2016
      • Enrollment Data 2016-2017
    • MOU
    • Virtual Classroom
    • Kalam Center
    • Practice Guidelines
    • MCI
    • DCI
    • INC
    • UGC
    • Others
    • Ph.D Program 2018
    • DH/DM Entrance Exam 2017
  • Exam
    • Examination Scheme
    • Examination Fee Details
    • Examination Result
    • Exam Notices
    • Annual Performance Report 2016-2017
  • Admission
  • Awards
    • Padma Vibhushan
    • Padma Bhushan
    • Padma Shri
    • BC Roy Award
    • Other Award
    • Chancellor Medal Awardees
    • Hewett Awardees
    • Alumni Award
  • Hospital
    • Overview
    • Cancer Institute
    • Application Form for (RAN) &(HMDG)
    • OPD
    • Trauma Emergency Services
    • Nursing
    • University Environment Department
    • Apex Virology Diagnostic Laboratory
    • Renal Transplant Waiting List
    • Liver Transplant Waiting List
  • Career
  • Newsroom
  • Tender

Quick Navigation

  • Library
  • Research
  • UG Teaching Schedule
  • Course/ Admission
  • Student Zone
  • Picture Gallery
  • Enrollment Data 2008-2013
  • Enrollment Data 2014-2015
  • MOU
  • Virtual Classroom
  • KALAM CENTER
  • Practice Guidelines
  • MCI
  • DCI
  • INC
  • UGC
  • Others
  • DHDM Entrance Exam
  • PNDTTEE 2016
Medical News
  • National Accrediation Board for Hospital and Healthcare Providers (NABH)

    National Accrediation Board for Hospital and Healthcare Providers (NABH)

    4th Edition December 2015

    November 01, 2018
  • Free Book PDF : CLINICAL MEDICINE

    Free Book PDF : CLINICAL MEDICINE

    A SYSTEM OF DIAGNOSIS by Dr Ashok Chandra

    August 23, 2018
  • Q. What adverse events are associated with osimertinib?

    Q. What adverse events are associated with osimertinib?

    A. In the trial by Mok et al., the safety profile for osimertinib was consistent with that reported previously and differed from that in the platinum-pemetrexed group. Overall, adverse events tended to be more severe in the platinum-pemetrexed group, despite the longer treatment duration with osimertinib. In the osimertinib group, the most commonly reported adverse events were diarrhea (in 113 patients [41%]), rash (in 94 [34%]), dry skin (in 65 [23%]), and paronychia (in 61 [22%]). Osimertinib was associated with a lower rate of adverse events leading to permanent discontinuation than was platinum-pemetrexed (in 19 patients [7%] and 14 patients [10%], respectively).

    February 21, 2017
  • Q. How does oral osimertinib compare to intravenous pemetrexed plus platinum therapy in patients with T790M-positive advanced non-small-cell lung cancer?

    Q. How does oral osimertinib compare to intravenous pemetrexed plus platinum therapy in patients with T790M-positive advanced non-small-cell lung cancer?

    A. In the trial by Mok et al., the authors found that patients with T790M-positive advanced non-small-cell lung cancer who received osimertinib had better response rates and a longer duration of progression-free survival than did those receiving platinum therapy plus pemetrexed after first-line EGFR-TKI therapy. The progression-free survival benefit with osimertinib was observed across all predefined subgroups, with hazard ratios of less than 0.50, including in patients with asymptomatic central nervous system metastases. In five prespecified measures of patient-reported symptoms, osimertinib had better results than platinum-pemetrexed.

    February 21, 2017
  • What is the standard first-line therapy for patients with advanced non-small-cell lung cancer with a mutant epidermal growth factor receptor (EGFR)?

    What is the standard first-line therapy for patients with advanced non-small-cell lung cancer with a mutant epidermal growth factor receptor (EGFR)?

    Among patients with advanced non-small-cell lung cancer with a mutant EGFR, EGFR tyrosine kinase inhibitors (TKIs) are the standard first-line therapy. Despite high tumor response rates with first-line EGFR-TKIs, disease progresses in a majority of patients after 9 to 13 months of treatment.

    What percentage of patients with advanced non–small-cell lung cancer and a mutant EGFR develop a T790M mutation?

    At the time of progression, about 60% of patients (regardless of race or ethnic background) are found to have a p.Thr790Met point mutation (T790M) in the gene encoding EGFR. The presence of the T790M variant reduces binding of first-generation or second-generation EGFR-TKIs to the ATP-binding pocket of EGFR, thereby reducing EGFR-TKI-mediated inhibition of downstream signaling and potentially leading to disease progression.

    February 20, 2017
  • Osimertinib in EGFR T790M - Positive Lung Cancer

    Osimertinib in EGFR T790M - Positive Lung Cancer

    Osimertinib is an oral, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR and T790M resistance mutations in patients with non-small-cell lung cancer. On the basis of results of phase 1 and phase 2 studies, the Food and Drug Administration approved osimertinib under the Breakthrough Therapy Designation Program. Mok et al. conducted a confirmatory, randomized, open-label, international, phase 3 trial (AURA 3) to show the superiority of osimertinib over platinum therapy plus pemetrexed (followed by optional pemetrexed maintenance) as standard of care for patients with centrally confirmed T790M-positive advanced non-small-cell lung cancer after first-line EGFR-TKI therapy.

    February 17, 2017
Back to Top

Leading Together for Brighter Future

KGMU

 

  • Home
  • FAQ's
  • Feedback
  • Contact
  • NIRF India 2016 Ranking

Copyright © 2016. All rights reserved